HEPA News and Press, Hepion Pharmaceuticals Inc.

Gaucho Group Holdings Inc. (VINO) is expected to report for Q1 2024 Tosoh Corporation (TOSCF) is expected to report for Q4 2024 Adidas AG ADR - Level I (ADDYY) is expected to report $0.69 for Q1 2024 MicroCloud Hologram Inc. (HOLO) is expected to report for Q1 2024 Universal Enter...

Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...

A look at the top 10 most actives in the United States AGBA Group Holding Limited (AGBA) rose 100.0% to $2.5 on volume of 201,539,290 shares PROSHARES TRUST (SQQQ) fell 2.9% to $12.47 on volume of 154,254,858 shares Tesla Inc. (TSLA) fell 3.4% to $142.05 on volume of 106,267,579 shares ...

2024-04-22 12:52:14 ET More on Mid-day movers & stocks. Marin Software Incorporated (MRIN) Q4 2023 Earnings Call Transcript WiSA signs its fifth WiSA E licensing deal with major consumer electronics company WiSA jumps on announcing fourth HDTV/PTV license with ma...

A look at the top 10 most actives in the United States Moolec Science SA (MLEC) rose 85.7% to $2.6 on volume of 50,077,650 shares SuperCom Ltd. (SPCB) rose 46.0% to $0.3212 on volume of 37,315,721 shares AGBA Group Holding Limited (AGBA) rose 35.2% to $1.69 on volume of 26,672,582 shares ...

2024-04-22 08:23:50 ET More on pre-market losers & stocks. Bio-Path Holdings Inc. (BPTH) Q4 2023 Earnings Call Transcript Bio-Path announces $1.2M registered direct offering priced at-the-market Bio-Path shares rally after clinical trial progress of BP1002 ...

2024-04-19 17:10:14 ET More on ContraVir Seeking Alpha’s Quant Rating on ContraVir Historical earnings data for ContraVir Financial information for ContraVir Read the full article on Seeking Alpha For further details see: Hepion ends Phase ...

EDISON, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic ...

2024-04-09 10:03:48 ET More on Madrigal Pharmaceuticals Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly I...

GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...